Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Atossa Therapeutics Q3 2026 Results: Net Loss of $5.64M, Loss Narrows

Atossa Therapeutics reported a net loss of $23.7 million for the nine months ended September 30, 2026, compared to $23.8 million in the prior year period. The company's cash position decreased significantly to $20.6 million, leading management to express substantial doubt about its ability to continue as a going concern without additional capital.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-5.6-8.7
Net income-5.6-8.7
EPS (diluted, $ a share)$-0.56$-1.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ATOS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Atossa Therapeutics, Inc.: key numbers

Share price
$1.93Close, Nov 16
Market cap
$19.3M
Shares outstanding
9.98MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Atossa Therapeutics, Inc.

All →
8:15 AM ET 8-K
Financial Results

Atossa Therapeutics Financial Results

Atossa Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its (Z)-endoxifen clinical programs. The company highlighted a new contingent value rights (CVR) agreement that entitles shareholders to 25% of net proceeds (up to $50 million) from the potential future sale of its first FDA priority review voucher.

Term
Q3 2026

“In recent weeks, we took meaningful steps to enable shareholders to participate in potential future value from our rare disease programs. Our recently announced contingent value rights agreement entitles holders to share in 25% of the net proceeds, up to $50 million, from the sale of the first priority review voucher awarded to Atossa from its rare disease development programs. At the same time, we continued to advance (Z)-endoxifen toward several near-term milestones, including anticipated FDA clearance of our IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027.”

Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer
8:15 AM ET 8-K
Dividend

Atossa Therapeutics Dividend

Atossa Therapeutics declared a dividend of one stapled contingent value right (CVR) for each share of common stock to participate in the potential future monetization of a priority review voucher. The CVRs entitle holders to 25% of the net proceeds from the sale or monetization of the first qualifying FDA priority review voucher awarded to the company, subject to an aggregate payment cap of $50 million. The rights are currently stapled to the common stock and expire on December 31, 2036, if no voucher is awarded.

Counterparty
VStock Transfer, LLC
Term
through Dec 2036
8:00 AM ET 8-K
Other 8-K Filing

Atossa Therapeutics Other 8-K Filing

Atossa Therapeutics announced a plan to issue one contingent value right (CVR) for each share of common stock, allowing shareholders to receive 25% of net proceeds from the potential monetization of its first qualifying FDA rare pediatric disease priority review voucher. The CVR payments are subject to an aggregate cap of $50 million and are tied to the company's (Z)-endoxifen development programs. The CVRs will be 'stapled' to the common stock and will not trade separately.

Term
through Dec 31, 2036
5:01 PM ET 8-K
Investor Presentation

Atossa Therapeutics Investor Presentation

Atossa Therapeutics made available an updated corporate and investor presentation on September 18, 2026, highlighting its clinical development strategy for (Z)-Endoxifen. The presentation covers the company's oncology core and rare disease expansion, including Phase 2 progress in breast cancer and regulatory designations for McCune-Albright Syndrome and Duchenne Muscular Dystrophy.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.